International journal of pediatric otorhinolaryngology · 2026
Juvenile recurrent respiratory papillomatosis treated with systemic bevacizumab: A single-center pediatric case series.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Almeida Flávia Jacqueline, Dos Santos Anna Carolinne Corrêa, Almeida Farias Camila Giuliana, de Matos Samantha Faria, de Morais Camila Ohomoto, de Jesus D'Elia Emmanuella, Argelazi Rachel Leirner, Arnoni Mariana Volpe, Jarovsky Daniel, Berezin Eitan Naaman, Schettini Isabela Hohlenwerger, Saliture Taciane Brinca Soares, da Silva Leonardo, Sáfadi Marco Aurélio Palazzi
Аннотация
BACKGROUND: Juvenile recurrent respiratory papillomatosis (JRRP) is a rare and potentially life-threatening disease caused by human papillomavirus (HPV) infection, most commonly types 6 and 11. Despite repeated surgical interventions, disease recurrence is frequent, and there is no curative treatment. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has emerged as a promising systemic therapy for severe cases.
METHODS: We conducted a retrospective analysis of pediatric patients (<18 years) with JRRP who received systemic bevacizumab between 2018 and 2025 at Santa Casa de São Paulo Hospital, Brazil. Clinical, demographic, and endoscopic data were collected from electronic medical records. Bevacizumab was administered monthly (5-10 mg/kg) according to a standardized protocol, and efficacy was evaluated by comparing lesion volume before and after treatment.
RESULTS: Thirteen patients were included, 69.2% male and 53.8% of African descent, with a median age at symptom onset of 18 months. All had lesions below the epiglottis, and 69.2% were tracheostomized. After 10 cycles of bevacizumab, all patients exhibited marked lesion reduction, with complete remission in 76.9%. The median number of surgical interventions decreased from 7.5 to 1.7 per year, and all tracheostomized patients were decannulated. Three patients required prolonged therapy due to persistent lesions, and no serious adverse events were observed.
CONCLUSIONS: Systemic bevacizumab demonstrated significant clinical efficacy and an acceptable safety profile in children with severe or recurrent JRRP. This series supports its use as an adjuvant therapy in refractory pediatric cases. Larger multicenter studies are warranted to determine optimal treatment duration and long-term outcomes.
METHODS: We conducted a retrospective analysis of pediatric patients (<18 years) with JRRP who received systemic bevacizumab between 2018 and 2025 at Santa Casa de São Paulo Hospital, Brazil. Clinical, demographic, and endoscopic data were collected from electronic medical records. Bevacizumab was administered monthly (5-10 mg/kg) according to a standardized protocol, and efficacy was evaluated by comparing lesion volume before and after treatment.
RESULTS: Thirteen patients were included, 69.2% male and 53.8% of African descent, with a median age at symptom onset of 18 months. All had lesions below the epiglottis, and 69.2% were tracheostomized. After 10 cycles of bevacizumab, all patients exhibited marked lesion reduction, with complete remission in 76.9%. The median number of surgical interventions decreased from 7.5 to 1.7 per year, and all tracheostomized patients were decannulated. Three patients required prolonged therapy due to persistent lesions, and no serious adverse events were observed.
CONCLUSIONS: Systemic bevacizumab demonstrated significant clinical efficacy and an acceptable safety profile in children with severe or recurrent JRRP. This series supports its use as an adjuvant therapy in refractory pediatric cases. Larger multicenter studies are warranted to determine optimal treatment duration and long-term outcomes.